FKFernanda Kreve

Fernanda Kreve

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fernanda Kreve has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sobrevivência a Longo Prazo após Transplante Ortotópico de Fígado: Análise de 20 anos em um Centro de Transplante em Campinas, Brasil

    by Victor Kenzo Ivano, Rafaela Hamada Jucá, Arthur Nunes Martins Neto, Fernanda Kreve, Tiago Diniz, Alexandre Foratto, Derli Conceição Munhoz, Eduardo Riccetto, Caique Fernandes Alves, Simone Reges Perales, et al.

    Introdução: O transplante ortotópico de fígado (TOF) é a principal terapia para doença hepática terminal. No Brasil, a realização de transplantes aumentou significativamente nas últimas décadas, com melhorias nos desfechos a longo prazo. Este estudo analisa a sobrevida de pacientes submetidos a TOF ao longo de 20 anos em um centro de referência. Métodos: Foram revisados os prontuários de 848 pacientes transplantados entre fevereiro de 1995 e dezembro de 2017. Aplicaram-se critérios de exclusão, incluindo pacientes com sobrevida inferior a 6 meses, visando minimizar o impacto de complicações precoces no desfecho de longo prazo. Dessa forma, 174 pacientes foram incluídos. As variáveis analisadas envolveram dados do receptor, doador, enxerto, procedimento cirúrgico e evolução pós-operatória. A sobrevida foi avaliada por Kaplan–Meier. Resultados: Dos 174 pacientes analisados, 98 (56,3%) mantiveram seguimento ambulatorial e 76 (43,7%) evoluíram a óbito. A média de idade no transplante foi de 47 anos, e 75% dos receptores eram do sexo masculino. As principais indicações foram hepatite viral (59,8%) e carcinoma hepatocelular (11,6%). A média do escore MELD foi 18. A principal causa de morte foi evento cardiovascular (36,4%), seguido de recidiva da doença hepática (22,1%) e neoplasias (15,6%). O tempo médio de sobrevida foi de 223 meses entre os pacientes vivos e 112 meses entre os óbitos (p < 0,0001). Maior tempo de isquemia fria, insuficiência renal pós-operatória, diabetes e maior tempo de internação em UTI foram fatores associados a pior sobrevida. Pacientes mais jovens apresentaram sobrevida significativamente superior (p = 0,00007). Conclusão: A análise de 20 anos mostrou que o TOF apresenta boa sobrevida a longo prazo, mas fatores como diabetes, disfunção renal e tempo prolongado de isquemia fria impactam negativamente os desfechos. Eventos cardiovasculares e recidiva da doença hepática foram as principais causas de mortalidade.

  • Open Access

    Long-Term Survival after Orthotopic Liver Transplant: 20-year analysis at a Transplant Center in Campinas, Brazil

    by Victor Kenzo Ivano, Rafaela Hamada Jucá, Arthur Nunes Martins Neto, Fernanda Kreve, Tiago Diniz, Alexandre Foratto, Derli Conceição Munhoz, Eduardo Riccetto, Caique Fernandes Alves, Simone Reges Perales, et al.

    Introduction: Orthotopic liver transplantation (OLT) is the primary therapy for end-stage liver disease. In Brazil, the number of liver transplants has significantly increased over the past decades, improving long-term outcomes. This study analyzes the long-term survival of patients who underwent OLT over 20 years at a reference transplant center. Methods: Medical records of 848 patients who underwent OLT between February 1995 and December 2017 were reviewed. Exclusion criteria included patients with survival below six months to minimize the impact of early postoperative complications on long-term outcomes. Thus, 174 patients were included. The analyzed variables involved the recipient, donor, graft, surgical procedure, and postoperative evolution. Survival was assessed using Kaplan–Meier analysis. Results: Among the 174 analyzed patients, 98 (56.3%) remained in outpatient follow-up, while 76 (43.7%) died. The mean age at transplantation was 47 years, and 75% of recipients were male. The main indications were viral hepatitis (59.8%) and hepatocellular carcinoma (11.6%). The mean MELD score was 18. The leading cause of death was cardiovascular events (36.4%), followed by liver disease recurrence (22.1%) and malignancies (15.6%). The mean survival time was 223 months for surviving patients and 112 months for deceased patients (p < 0.0001). Longer cold ischemia time, postoperative renal dysfunction, diabetes, and prolonged stay in the intensive care unit were associated with worse survival. Younger patients had significantly longer survival (p = 0.00007). Conclusion: The 20-year analysis demonstrated that OLT provides good long-term survival; however, factors such as diabetes, renal dysfunction, and prolonged cold ischemia time negatively impact the outcomes. Cardiovascular events and recurrence of liver disease were the leading causes of mortality.

  • Open Access

    Trajectory of NAFLD characteristics after Roux-en-Y gastric bypass: a five-year historical cohort study

    by Fernanda Kreve, Guilherme Hoverter Callejas, Laísa Simakawa Jimenez, Rodolfo Araújo Marques, Felipe David Mendonça Chaim, Murillo Pimentel Utrini, Martinho Antonio Gestic, Almino Cardoso Ramos, Elinton Adami Chaim, Everton Cazzo

    BACKGROUND: The long-term effects of bariatric surgery on the course of non-alcoholic fatty hepatopa-thy (NAFLD) are not fully understood.OBJECTIVE: To analyze the evolution of NAFLD characteristics through noninvasive markers after Roux-en-Y gastric bypass (RYGB) over a five-year period.DESIGN AND SETTING: Historical cohort study; tertiary-level university hospital.METHODS: The evolution of NAFLD-related characteristics was evaluated among 49 individuals who un-derwent RYGB, with a five-year follow-up. Steatosis was evaluated through the hepatic steatosis index (HSI), steatohepatitis through the clinical score for non-alcoholic steatohepatitis (C-NASH) and fibrosis through the NAFLD fibrosis score (NFS).RESULTS: 91.8% of the individuals were female. The mean age was 38.3 +/- 10 years and average body mass index (BMI), 37.4 +/- 2.3 kg/m2. HSI significantly decreased from 47.15 +/- 4.27 to 36.03 +/- 3.72 at 12 months (P < 0.01), without other significant changes up to 60 months. C-NASH significantly decreased from 0.75 +/- 1.25 to 0.29 +/- 0.7 at 12 months (P < 0.01), without other significant changes up to 60 months. NFS de-creased from 1.14 +/- 1.23 to 0.27 +/- 0.99 at 12 months (P < 0.01), and then followed a slightly ascending course, with a marked increase by 60 months (0.82 +/- 0.89), but still lower than at baseline (P < 0.05). HSI variation strongly correlated with the five-year percentage total weight loss (R = 0.8; P < 0.0001).CONCLUSION: RYGB led to significant improvement of steatosis, steatohepatitis and fibrosis after five years. Fibrosis was the most refractory abnormality, with a slightly ascending trend after two years. Steato-sis improvement directly correlated with weight loss.